Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy.
Infectious Diseases Unit, Padova Hospital, Via Giustiniani, 2, 35128, Padova, Italy.
Med Microbiol Immunol. 2018 Aug;207(3-4):183-194. doi: 10.1007/s00430-018-0538-1. Epub 2018 Mar 9.
Soluble CD163, soluble CD14 and cellular HIV-1-DNA levels reflect two different aspects of HIV infection: immune activation and the reservoir of infected cells. The aim of this study was to describe their relationships in a cohort of HIV-HCV co-infected patients successfully treated for both HCV and HIV infections. Fifty-five patients were recruited and studied prior to the start of direct-acting antivirals (DAAs) (T0), at week 12 of DAA treatment (T1) and 24 weeks after T0 (T2). The subjects were classified as having undetectable plasma HIV viraemia (UV) or low-level viraemia (LLV) in the 18 months before T2. Plasma levels of sCD163 and of sCD14 were comparable in patients with UV and in subjects with LVL at T0, T1 and T2. The HIV DNA level was positively correlated with LLV but not with sCD163 and sCD14 levels; these two markers of inflammation were positively correlated (p = 0.017). Soluble CD163 and sCD14 decreased over time from T0 to T2 (p = 0.000 and p = 0.034, respectively). In conclusion, the significant decrease in sCD163 and sCD14 levels in patients cured of HCV infection, regardless of the presence of LLV, suggests a main role for HCV in immune activation in HIV-HCV co-infected patients.
可溶性 CD163、可溶性 CD14 和细胞内 HIV-1-DNA 水平反映了 HIV 感染的两个不同方面：免疫激活和受感染细胞的储存库。本研究的目的是描述在成功治疗 HCV 和 HIV 感染的 HIV-HCV 合并感染患者队列中它们之间的关系。招募了 55 名患者，并在开始直接作用抗病毒药物 (DAA) 治疗前 (T0)、DAA 治疗的第 12 周 (T1) 和 T0 后 24 周 (T2) 进行了研究。在 T2 前 18 个月，将受试者分为 HIV 血浆病毒血症不可检测 (UV) 或低水平病毒血症 (LLV)。在 T0、T1 和 T2 时，具有 UV 的患者和具有 LLV 的患者的血浆 sCD163 和 sCD14 水平相当。HIV DNA 水平与 LLV 呈正相关，但与 sCD163 和 sCD14 水平无关；这两个炎症标志物呈正相关（p=0.017）。可溶性 CD163 和 sCD14 从 T0 到 T2 呈时间依赖性下降（p=0.000 和 p=0.034）。总之，无论是否存在 LLV，HCV 感染治愈患者的 sCD163 和 sCD14 水平显著下降，这表明 HCV 在 HIV-HCV 合并感染患者的免疫激活中起主要作用。
